Most Popular
Newsletter
Cyagen’s Checklist for Your Return to the Lab
Jul 31, 2020
As scientists around the world continue to grapple with the implications of COVID-19 on their research, Cyagen remains available to assist with all your needs for in vivo model services and products. Our expert support team understands that researchers worldwide are up against many different barriers in starting their projects. Read More >
Newsletter
New Cyagen Knockout Catalog Model Publication Alert – July 2020
Jul 28, 2020
From January through June of 2020, Cyagen received over 70 citations for our animal models, contributing to many advances across research fields. We have put together the below list of articles from high impact factor (IF) journals to provide insights into a variety of mouse model types, gene targets, research applications, and some of the most recent developments shown in scientific literature. Read More >
COVID-19
Newsletter
COVID-19 Resource List for Researchers – ACE2 Animal Models and More
Jul 27, 2020
The pneumonia-like COVID-19 caused by the novel coronavirus (SARS-CoV-2) remains a huge medical challenge worldwide. To provide a wholistic guide for developing clinical treatments, vaccines, and antiviral drugs, it is of great significance to study the interaction mechanisms between severe acute respiratory syndrome (SARS) coronaviruses and host molecules, while also exploring the pathogenic process of coronaviruses. Read More >
Research Trend
Newsletter
Applications of Humanized Mouse Models in Drug Development Research
Jul 16, 2020
Humanized mice can be developed through a variety of genetic modification techniques, wherein human genes may directly replace endogenous mouse genes or be inserted into a safe locus, such as Rosa26. Read More >
Newsletter
Advantages of TurboKnockout® Gene Targeting Mice
Jun 28, 2020
The TurboKnockout® gene targeting service by Cyagen is based on traditional embryonic stem cell (ESC)-mediated targeting techniques, which can be used for complex gene knockout projects to provide C57BL/6 or (new) BALB/c mouse models with accurate genetic modification and no off-target effects. Read More >
Newsletter
New Cyagen Mice Publication Alert – June 2020
Jun 19, 2020
The following publications demonstrate the use of custom genetically modified mouse and rat models across a broad range of human disease studies, including immunological disorders, inflammatory disorders, cardiovascular disease, oncology, immunology, and liver disease. Read More >
Newsletter
Breaking News
Cyagen Announces Support of Rare Genomic Institute’s BeHEARD Competition – Rare Disease Science Technology Grants Challenge
May 18, 2020
Cyagen Biosciences has committed to donate up to $83,250 of mouse model vector construction services as prizes for the Rare Genomic Institute’s BeHEARD (Helping Empower and Accelerate Research Discoveries) Challenge, which provides technology and financial grants for rare disease research. Read More >
Newsletter
COVID-19
Cyagen to Remain Fully Operational Throughout COVID-19
Apr 27, 2020
Despite the effects of COVID-19 on global business, we are operating at 100% proficiency - providing uninterrupted production and technical support to ensure that your research continues. We will continue serving your model generation, cloning, and virus packaging needs with the same high quality and fast turnaround as before the outbreak. Read More >
Newsletter
Research Trend
Applications of Sirtuins (SIRT) Knockout Mouse Models in Disease Research
Apr 07, 2020
Sirtuins - colloquially known as the longevity genes – are a highly conserved family of NAD1+-dependent enzymes which are involved in the regulation of gene silencing, metabolism, cell division, apoptosis, and genetic material repair. Additionally, it has been reported that sirtuins play important roles in the development of multi-systemic diseases. Read More >
Newsletter
Research Trend
COVID-19
Beyond Mediating Host Cell Entry of SARS-CoV-2: What Roles Does ACE2 Play?
Apr 01, 2020
In our fight against the virus and COVID-19, researchers have studied the SARS-CoV-2 virus itself and its host receptor, ACE2, from the aspects of epidemiology, pathology, virus traceability, prevention, and control measures. The human ACE2 receptor is known to interact with SARS-CoV-2 and permit its initial cell entry, making it particularly important to explore its function. Read More >